Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04874077|
Recruitment Status : Recruiting
First Posted : May 5, 2021
Last Update Posted : May 7, 2021
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Depression and anxiety disorders are among the most prevalent of all mental disorders, with an estimated annual prevalence of 9.7% and 18.1% respectively.
It has been known for the last 100 years that depression and anxiety both likely affect vocal acoustic properties. In 1921, Emil Kraepelin, characterized depressed patient's voices as having a lower pitch, lower volume, lower rate of speech, more monotony of prosody as well as more hesitations, stuttering, and whispering.
Mechanistically, it is possible that the neural circuitry involved in the pathophysiology of mood and anxiety disorders impinge upon the neural circuit involved in speech production, affecting qualities that include rate, prosody, speech latency and other paralinguistic features. Thus, acoustic features of speech may be one of the more readily accessible biomarkers for these conditions.
Given this understanding, the investigators sought to develop a passive vocal biomarker instrument for depression and anxiety screening that could markedly expand access as well as standardize the quality of screening in primary care settings.
|Condition or disease|
|Major Depressive Disorder|
|Study Type :||Observational|
|Estimated Enrollment :||225 participants|
|Official Title:||Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder: A Multi-Site Fully Remote E-Clinical Validation Study|
|Actual Study Start Date :||April 21, 2021|
|Estimated Primary Completion Date :||June 21, 2021|
|Estimated Study Completion Date :||July 21, 2021|
- Sensitivity and specificity of the Kintsugi's technology's prediction [ Time Frame: July 30, 2021 ]Sensitivity and specificity of the Kintsugi's technology's prediction compared to DSM-5 diagnosis of depression.
- Sensitivity and specificity to depression at the PHQ-9 score of 10 [ Time Frame: July 30, 2021 ]Sensitivity and specificity of the Kintsugi's technology's prediction compared to PHQ-9 scores at a cutoff threshold of 10
- Sensitivity and specificity to depression at the GAD-7 score of 10 [ Time Frame: July 30, 2021 ]Sensitivity and specificity of the Kintsugi's technology's prediction compared to GAD-7 scores at a cutoff threshold of 10
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04874077
|Contact: Grace Chang||(415) firstname.lastname@example.org|
|United States, California|
|San Francisco Psychiatrists, Inc.||Recruiting|
|San Francisco, California, United States, 94123|
|Contact: Girish Subramanyan, MD|
|United States, Montana|
|Frontier Psychiatry||Not yet recruiting|
|Billings, Montana, United States, 59101|
|Contact: Reza Hosseini Ghomi, MD|